Editas Medicine, Inc. (NASDAQ:EDIT) Receives $15.00 Average Target Price from AnalystsTicker Report • 29 days ago
Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat reports...
Share to Feed
A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have lost about 26.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue...
Editas Medicine, Inc. (NASDAQ:EDIT Free Report) Analysts at Zacks Research decreased their Q1 2024 earnings estimates for Editas Medicine in a research note issued on Wednesday...
Investors in Editas Medicine Inc (EDIT) saw new options begin trading this week, for the May 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options...
Editas Medicine, Inc. (NASDAQ:EDIT Get Free Report) saw a large increase in short interest during the month of February. As of February 29th, there was short interest totalling 13,520,000...
Editas Medicine (NASDAQ:EDIT Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA Get Free Report) are both small-cap medical companies, but which is the superior stock? We will...
This is a Bearish indicator signaling EDIT's price could decline from here. Traders may explore shorting the stock or put options...
This is a signal that EDIT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
This indicator may be signaling that EDIT's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
We wouldn't blame Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders if they were a little worried about the fact that...